Mayo Clinic Q and A: Defining head and neck cancer
DEAR MAYO CLINIC: A co-worker recently was diagnosed with oral cancer after a nagging cough led him to the doctor. It got me wondering about the incidence of head and neck cancer and what I should be screened for. I'm in my mid-40s and try to be mindful of getting an annual physical. ANSWER: There are many types of head and neck cancers, which is a broad category used to describe any cancer that starts in the… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 16, 2023 Category: Databases & Libraries Source Type: news
Mayo Clinic Minute: Innovative technology to treat head and neck cancers
In the U.S., HPV is linked to about 70% of throat and mouth cancers. And more than 70% of those cancers are diagnosed in men, according to the Centers for Disease Control and Prevention. Treatment for throat and mouth cancers, also referred to as oropharyngeal or head and neck cancers, depends on location and stage of the cancer as well as other factors. Dr. Phillip Pirgousis, a Mayo Clinic head and neck surgeon, says patients now have safer, less invasive surgical treatments… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 11, 2023 Category: Databases & Libraries Source Type: news
Mayo Clinic study suggests improved time efficiency, accuracy with AI-automated head and neck radiotherapy model
ROCHESTER, Minn. — A study conducted by Mayo Clinic suggests artificial intelligence could potentially improve time efficiency and standardization for radiation therapy planning in patients with head and neck cancers. The validation study, published in Frontiers in Oncology, evaluated the efficiency of an algorith m trained by Mayo Clinic and developed in collaboration with Google Health. Radiation therapy planning for head and neck cancers requires a heavy time investment from multiple specialty areas due to the… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - April 27, 2023 Category: Research Source Type: news
Model Can Predict Postoperative RT Delay in Head & Neck Cancer
MONDAY, April 24, 2023 -- A model incorporating individual-level factors with health literacy and community-level factors predicts postoperative radiation therapy (PORT) delay for patients with head and neck squamous cell carcinoma (HNSCC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2023 Category: Pharmaceuticals Source Type: news
Consumer Health: 3 types of head and neck cancers
April is Head and Neck Cancer Awareness Month, which makes this a good time to learn about three types of cancer that affect these areas of the body. Head and neck cancers account for nearly 4% of all cancers in the U.S., according to the National Cancer Institute. These cancers are more than twice as common among men as women, and are diagnosed more often among people over 50. Among the many types of head and neck cancers are… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 19, 2023 Category: Databases & Libraries Source Type: news
Novel Bispecific Antibody Active in Recurrent/Metastatic Head and Neck Cancer
(MedPage Today) -- ORLANDO -- More than a third of patients with previously treated head and neck cancer responded to a novel bispecific antibody, a preliminary clinical trial showed.
The data showed that 37.2% of patients had objective responses... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - April 18, 2023 Category: Surgery Source Type: news
HPV infection may cause throat, mouth cancer
3D illustration of the human papillomavirus (HPV). April is Head and Neck Cancer Awareness Month. Head and neck cancers, including mouth and throat, occur in the head and neck region. You may have heard about the connection between HPV infection and certain types of cervical cancer, but did you know HPV infection is also related to a higher risk of throat and mouth cancer? To prevent these cancers, the Centers for Disease Control and Prevention (CDC) recommends that all… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 14, 2023 Category: Databases & Libraries Source Type: news
Drug Combo Shows Promise Against Advanced Head and Neck Cancer
MONDAY, April 3, 2023 -- An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says.
Ficlatuzumab used in combination with the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 3, 2023 Category: General Medicine Source Type: news
How can cancer teams ensure that patients' preferences inform treatment decisions?
This study focused on head and neck cancer. Researchers observed multidisciplinary teams making treatment decisions and assessed patients ' engagement with their recommendations.
The study found that team meetings were frequently dominated by doctors ' opinions on the best treatment. Patients tended to be presented with the team ' s preferred treatment option, rather than all treatment options; their preferences often did not inform treatment decisions.
The researchers call for healthcare professionals to find ways to ensure that patient preferences inform decision-making. Training for professionals on shared decision-ma...
Source: Current Awareness Service for Health (CASH) - March 20, 2023 Category: Consumer Health News Source Type: news
Alembic Pharma gets USFDA nod to market generic cancer drug
Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2023 Category: Pharmaceuticals Source Type: news
Double Test for HPV in Head and Neck Cancer to Optimize Care Double Test for HPV in Head and Neck Cancer to Optimize Care
Patients with head and neck cancer who have equivocal results on routine p16 assay for HPV should be tested again with a test that measures HPV DNA, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Social Vulnerability Tied to Worse Pediatric Head and Neck Cancer Outcomes
WEDNESDAY, Feb. 22, 2023 -- Among pediatric patients with head and neck cancers (HNCs), increasing social vulnerability is associated with significant decreases in receipt of care and survival time, according to a study published online Feb. 17 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2023 Category: Pharmaceuticals Source Type: news
Adding Docetaxel to RT Improves Survival in Cisplatin-Ineligible Head & Neck Cancer
(MedPage Today) -- Adding docetaxel to radiation therapy (RT) improved survival outcomes in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, a phase III randomized trial showed.
At a median follow-up of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 4, 2023 Category: Hematology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news